26 October 2026RSS feed
PR●Press Release IndiaTHE BUSINESS ANNOUNCEMENT WIRE
Business announcements.
Direct from the source.
NEWSROOM / INDIA

The latest on the wire

Announcements from businesses shaping what comes next.

UPDATED THROUGHOUT THE DAY
Business wire1127

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda's Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1

This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment Options Oveporexton is an Orexin Agonist Designed to Restore Orexin Signaling and Address the Underlying Orexin Deficiency that Causes Narcolepsy T